Promega, JA2151, CD40 Bioassay

Simple Bioassay, Consistent Results
The CD40 Bioassay is a bioluminescent cell-based assay that measures potency and stability of ligands or agonist antibodies and other biologics that can bind and activate CD40. CD40 is expressed on the surface of B cells, dendritic cells and monocytes and is a member of the tumor necrosis factor receptor superfamily. CD40 ligand (CD154) is the primary ligand for CD40 and is expressed by activated T cells, critical regulators of cellular and humoral immunity. Signaling via CD40 triggers activation of antigen-presenting cells (APC).
Agonist CD40 antibodies can mimic the CD40 ligand and are capable of substituting for CD4+ helper T cells in murine models of T cell-mediated immunity. Therefore, agonist CD40 antibodies can rescue the function of APC in tumor-bearing hosts and restore effective immune responses against tumor antigens. Subsequent data from multiple preclinical models has demonstrated synergistic enhancement from combining CD40 agonists with cytotoxics, especially in chemotherapy.
The CD40 Bioassay reflects the mechanism of action (MOA) of biologics designed to activate the CD40 receptor.
Control Ab, Anti-CD40, is a mouse anti-human CD40 agonist antibody. It can be used as a positive control in the CD40 Bioassay in the presence of FcγRIIb CHO-K1 Cells (Cat.# J2232, JA2251, JA2255).